Navigation Links
According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients

EXTON, Pa., Dec. 19, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q4 2013, Roche/Genentech's Perjeta in combination with Roche/Genentech's Herceptin and docetaxel is prescribed to over one-third of first-line HER2-positive, hormone-receptor (HR)-negative advanced/metastatic breast cancer patients. Findings in the same HER2-positive, HR-negative population reveal that Roche/Genentech's Kadcyla has become the patient-share leader in the second-line setting. Surveyed oncologists also reported that Novartis's Afinitor holds modest patient shares in the second- and third-line settings for HR-positive, HER2-negative breast cancer.


The TreatmentTrends® Advanced/Metastatic Breast Cancer (US) Q3 2013  report, in which 100 medical oncologists were surveyed about their current and expected treatment practices for breast cancer, also finds that out-of-pocket costs to patients is one of the top three main obstacles that prevent surveyed physicians from prescribing currently available premium-priced treatments for advanced/metastatic breast cancer. Notably, other key obstacles to prescribing were safety/tolerability and managed care/prior authorization problems.

"The market entry of several novel targeted agents with strong efficacy data in the last 18 months is changing previous treatment paradigms," said Decision Resources Group Principal Business Insights Analyst Amy Duval, M.Res. "These new market entries command premium prices, and some cost-related issues are obstacles to prescribing for surveyed oncologists."

TreatmentTrends® Advanced/Metastatic Breast Cancer is a syndicated report designed to provide a view of the current and future management of breast cancer based on primary research fielded with 100 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Perjeta and Kadcyla through its LaunchTrends® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shingles Vaccine is Safe, According to New Study
2. Vaccines are dangerous, according to - Get all the facts!
3. Vaginal Mesh Lawsuits Pick Up Momentum, According To Pulaski & Middleman, LLC
4. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to
5. Over 123 Million Medical Device Units Recalled in Second Quarter of 2012, Reaching an Eight-Quarter High, According to the ExpertRECALL Index
6. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
7. European Market for Dental Instruments Surpasses $652 Million, According to New Market Research
8. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
9. Food Recalls Rise to Four a Day in Third Quarter, Reaching Highest Level of Activity in Eight Quarters, According to the ExpertRECALL Index
10. Affluence, an Aging Population, and Anticipated Rx-to-OTC Switches Boost a Healthy $32 Billion OTC Market in China, According to Kline
11. Life Sciences Venture Capital Funding Drops 14% During 2012, According To The MoneyTree Report
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
Breaking Medicine Technology:
(Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... Neb. (PRWEB) , ... November 25, 2015 , ... ... staffing companies, has been recognized once again for its stellar workplace culture with ... to Work.” , Medical Solutions’ Cincinnati office was named a finalist ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
Breaking Medicine News(10 mins):